Rapid Intravascular Cooling in Myocardial Infarction as Adjunctive to Percutaneous Coronary Intervention

Overview

Rapid MI-ICE-Pilot is designed to demonstrate the safety and efficacy of the Celsius Control™ System (CCS) endovascular catheter to reduce the infarct size resulting from acute anterior myocardial infarction when used in combination with cold saline as an adjunct to immediate percutaneous coronary intervention (PCI) in patients with an occluded infarct-related artery.

Full Title of Study: “A Randomized, Controlled Study of the Use of Central Venous Catheter Core Cooling Combined With Cold Saline, and Rewarming as an Adjunct to Percutaneous Coronary Intervention For the Treatment of Acute Myocardial Infarction”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2009

Detailed Description

The CCS is an endovascular thermal control system that circulates cooled saline through an indwelling central venous catheter in a closed-loop manner. The system has received 510(k) approval from the FDA for use in temperature management in neuro-surgical and cardiac patients during surgery and in recovery/intensive care. It has also received European CE mark and Australian TGA approval. Animal data in a model of acute myocardial infraction support the hypothesis that rapid cooling, prior to acute PCI, may reduce infarct size. Meta-analysis of the previous acute MI trials ICE-IT (N = 228; 1:1 randomization, hypothermia : control, Innercool Therapies, Inc.) and COOL MI-I (Radiant Medical, Inc) suggests there is a reduction in infarct size as measured by 30-day SPECT in the population of patients with anterior MIs who were cooled below 35 C prior to PCI. This study is designed to investigate the safety, feasibility and efficacy of rapid endovascular cooling in the setting of acute PCI in patients with anterior infarctions.

Interventions

  • Device: Endovascular cooling by the Celsius Control System
  • Other: Standard of care

Arms, Groups and Cohorts

  • Experimental: patients with acute STEMI – treatment with Hypothermia +PCI
    • Hypothermia using endovascular cooling with the Celsius Control System as an adjunct therapy. Hypothermia before reperfusion by a combination of infusion of cold saline and endovascular catheter cooling as an adjunct therapy in patients with a STEMI scheduled to undergo primary percutaneous coronary intervention (PCI).
  • Active Comparator: Patients with an acute STEMI eligible for primary PCI
    • Standard of care treatment or the control group Patients with an acute STEMI eligible for primary PCI

Clinical Trial Outcome Measures

Primary Measures

  • Cardiac MRI infarct size
    • Time Frame: Day 4
    • reduction in infarct size as a percentage of left ventricle size in the per protocol population.

Secondary Measures

  • MRI infarct size
    • Time Frame: Day 4
    • Infarct size as percent of area at risk determined with T2-weighted MRI in per protocol population
  • Myocardial necrosis
    • Time Frame: 24 Hours
    • CK-MB release through 24 hours as area under the curve
  • NYHA/AHA Cardiac Functional Class
    • Time Frame: Day 30
    • used to describe stages of Heart Failure ( Class I, II, III and IV)
  • Major Adverse Cardiac Events (MACE)
    • Time Frame: Month 12
    • MACE: Death, MI, re-hospitalization
  • Angiographic outcomes
    • Time Frame: Day 1
    • TIMI flow grade, TIMI myocardial perfusion grade
  • ST-segment resolution
    • Time Frame: Day 1
    • ST-segment resolution as a function of time

Participating in This Clinical Trial

Inclusion Criteria

Each eligible patient must meet the following inclusion criteria : 1. Have ECG evidence of ongoing acute anterior myocardial infarction, involving a large area of myocardium, as defined by the following ECG criteria: a. Anterior infarct: ST-segment elevation >0.2mV measured 0.08 sec after the J point in 2 or more anatomically contiguous precordial leads, V1 through V4; and/or >0.2mV in lead V5 V6 2. Present to the RAPID MI-ICE site within six (6) hours of the onset of acute cardiac ischemic signs or symptoms (such as chest pain or pressure, arm or jaw pain, dyspnea, nausea/vomiting, or syncope) 3. Be a candidate for PCI and have PCI planned as the immediate intervention. 4. Be willing and able to comply with study procedures, including returning for the MRI scan at 4 ±2 days and return for the clinical examination on Day 30 5. Provide written informed consent prior to the initiation of study-specific procedures 6. Be in Killips Class I Exclusion Criteria:

Patients are not eligible for the study if they meet one or more of the following criteria: 1. Age less than eighteen (<18) years of age 2. Age greater than seventy-five (>75) years of age 3. Are pregnant 4. Have a suspected aortic dissection 5. History of a prior anterior myocardial infarct or prior large myocardial infarct. 6. The suspected etiology of myocardial infarction is primarily related to substance abuse (e.g., cocaine, methamphetamine, etc.) 7. Acute administration of a thrombolytic agent for the qualifying MI 8. If (during the screening process) the determination is made by site-study personnel that initiation of cooling prior to diagnostic coronary angiography is technically not feasible for any reason (should the patient be randomized to the Hypothermia Arm), the prospective subject should not be enrolled 9. Require an immediate surgical or procedural intervention other than PCI (e.g. CABG) 10. Present in cardiogenic shock or with end-stage cardiomyopathy 11. Have undergone at least ten (10) minutes of cardiopulmonary resuscitation (CPR) prior to presentation to the PCI facility 12. History of previous MI with known, pre-existing, anterior pathologic Q-waves 13. History of surgical coronary artery revascularization (e.g., CABG, MIDCAB, or OPCAB) 14. Recent stroke (within 3 months) 15. Active bleeding, coagulopathy, or other contraindication to the placement of a heparin-coated 14F central venous catheter via a 14F femoral venous introducer sheath (e.g., known history of heparin induced thrombocytopenia, or IVC filter) 16. Contraindications to hypothermia, such as patients with known hematologic dyscrasias which affect thrombosis (e.g., cryoglobulinemia, sickle cell disease, serum cold agglutinins) or vasospastic disorders (such as Raynaud's or thromboangitis obliterans) 17. Personal or familial history of malignant hyperthermia 18. Known end-stage renal disease (ESRD; e.g., on dialysis, or status-post renal transplant), known hepatic failure (e.g., cirrhosis, or acute hepatitis), or any other contraindication to receiving meperidine (such as use of MAO inhibitors within previous 14 days, history of seizures, history of hypersensitivity to meperidine, etc.) [Note: Patients with a contraindication to buspirone administration may be enrolled but should not be given buspirone as part of the anti-shivering regimen.] 19. Any other acute or chronic condition which the Investigator believes will unacceptably increase the risk of study participation or interfere with study procedures and assessments 20. Deemed unsuitable by the investigators to participate in the study. 21. Signs of cardiogenic shock or other signs of significant heart failure such as rales over the lungs 22. Active or recent (within 1 month prior to study enrollment) participation in another investigational clinical research study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • ZOLL Circulation, Inc., USA
  • Collaborator
    • Lund University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Goran K Olivecrona, MD, Principal Investigator, Department of Cardiology, Lund University Hospital
    • David Erlinge, MD, PhD, Principal Investigator, Department of Cardiology, Lund University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.